Soft Tissue Sarcoma

DSRCT, although rare, is noted for aggressiveness and rapid progression and therefore should ideally be considered in the differential diagnosis of bloody ascites in young male patients, even when initial cytology is negative. Early application of diagnostic laparoscopy and biopsy may facilitate timely tissue diagnosis, particularly when imaging mimics peritoneal carcinomatosis.

This study reveals age-related molecular and tumor microenvironment differences in SS that may contribute to disparities in clinical outcomes. These findings underscore the need for further studies to validate these results and to support the development of age-tailored therapeutic strategies.

P1, N=15, Completed, The University of Sydney | Recruiting --> Completed

P1, N=48, Not yet recruiting, A-Seeds Australia Pty Ltd

P1, N=62, Not yet recruiting, Novartis Pharma AG | N=27 --> 62

P=N/A, N=60, Recruiting, Universitaire Ziekenhuizen KU Leuven | Trial completion date: Jul 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Dec 2026

P2, N=145, Recruiting, University Health Network, Toronto | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2026 --> Nov 2027

Significant synergistic effects were observed when GCLC inhibitors were combined with agents targeting the GSH synthesis pathway, specifically SLC7A11 inhibitors and the glutaminase inhibitor telaglenastat...These findings highlight the vulnerability of glutathione metabolism in SMARCB1-deficient cancers, suggesting that a GCLC inhibitor may be a promising therapeutic option. This study provides a preclinical foundation for the development of effective treatment strategies for SMARCB1-deficient cancers, including combination therapies, and supports further investigation toward future translational applications.

This review article focuses on four fusion-driven soft tissue tumors which illustrate different aspects of our evolving understanding of these tumors: (1) NUTM1-rearranged sarcoma, a prototypical example of a novel, clinically significant entity defined almost entirely by molecular genetics; (2) SRF-rearranged myoid neoplasm, an entity whose recognition greatly clarifies our understanding of pediatric "leiomyosarcomas;" (3) superficial FET-ETS neurocristic tumor, a very recently described, clinically benign entity sharing identical fusion events with often-lethal Ewing sarcoma; and (4) an evolving family of glomoid/myoid neoplasms harboring EWSR1::WT1 fusions, but clearly differing from desmoplastic small round cell tumor. These examples illustrate the complexity of fusion-driven soft tissue tumors and the importance of integrating molecular genetic testing with other clinicopathological data, rather than viewing it in isolation.

Complete surgical resection provides excellent outcomes with a low risk of complications or recurrence. Mazabraud syndrome should be considered in patients with multiple or recurrent IMMs and GNAS mutations.

P=N/A, N=72, Recruiting, Mayo Clinic | Trial completion date: Aug 2028 --> Aug 2031

Ovarian DSRCT poses diagnostic challenges due to histomorphological mimicry of common malignancies. Although this subclassification may aid prognostication, multicenter validation is warranted.